Limits...
Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.

Choi YJ, Oh IK, Oh JR, Huh K - Korean J Ophthalmol (2006)

Bottom Line: Visual acuity and intraocular pressure (IOP) were also measured.Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection.The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.

ABSTRACT

Purpose: To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.

Methods: This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular pressure (IOP) were also measured.

Results: Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection.

Conclusions: The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.

Show MeSH

Related in: MedlinePlus

Visual acuity in the intravitreal and posterior sub-tenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2908852&req=5

Figure 1: Visual acuity in the intravitreal and posterior sub-tenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.

Mentions: The mean (±SD) visual acuity before triamcinolone acetonide injection and at 1 week, 1 month and 3 months thereafter is shown in Table 2 and Fig. 1. The mean baseline visual acuity was not significantly different between the 2 groups (p=0.338). In both groups, the visual acuity significantly improved throughout the study. In the intravitreal injection group, the mean visual acuity at 1 month (0.571±0.393; p=0.001) and 3 months (0.535±0.382; p=0.001) after the injection were significantly better than baseline measurements. In the posterior subtenon injection group, the mean visual acuity at 1 month (0.650±0.281; p=0.011) and 3 months (0.623±0.264; p=0.007) after the injection was also significantly better than the baseline measurements. Between the 2 groups, there were no significant differences in the mean visual acuity changes before injection or at 1 month and 3 months after injection.


Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.

Choi YJ, Oh IK, Oh JR, Huh K - Korean J Ophthalmol (2006)

Visual acuity in the intravitreal and posterior sub-tenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2908852&req=5

Figure 1: Visual acuity in the intravitreal and posterior sub-tenon injected eyes at baseline and at 1 and 3 months after triamcinolone acetonide injection.
Mentions: The mean (±SD) visual acuity before triamcinolone acetonide injection and at 1 week, 1 month and 3 months thereafter is shown in Table 2 and Fig. 1. The mean baseline visual acuity was not significantly different between the 2 groups (p=0.338). In both groups, the visual acuity significantly improved throughout the study. In the intravitreal injection group, the mean visual acuity at 1 month (0.571±0.393; p=0.001) and 3 months (0.535±0.382; p=0.001) after the injection were significantly better than baseline measurements. In the posterior subtenon injection group, the mean visual acuity at 1 month (0.650±0.281; p=0.011) and 3 months (0.623±0.264; p=0.007) after the injection was also significantly better than the baseline measurements. Between the 2 groups, there were no significant differences in the mean visual acuity changes before injection or at 1 month and 3 months after injection.

Bottom Line: Visual acuity and intraocular pressure (IOP) were also measured.Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection.The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea.

ABSTRACT

Purpose: To compare the short-term effects of intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema.

Methods: This is a prospective and interventional study. Sixty eyes of 60 patients who had diffuse diabetic macular edema were assigned to receive a single intravitreal injection (4 mg) or a single posterior subtenon injection (40 mg) of triamcinolone acetonide. The central retinal thickness was measured using optical coherent tomography before injection and at 1 and 3 months after injection. Visual acuity and intraocular pressure (IOP) were also measured.

Results: Both intravitreal and posterior subtenon injections of triamcinolone acetonide resulted in significant improvements in visual acuity at 1 month and 3 months after injection. Both groups resulted in a significant decrease in central macular thickness (CMT) at 1 month and 3 months post-injection. IOP in the intravitreal injection group was significantly higher than in the posterior subtenon injection group at 3 months after injection.

Conclusions: The posterior subtenon injection of triamcinolone acetonide had a comparable effect to the intravitreal triamcinolone injection and showed a lower risk of elevated IOP. Posterior subtenon injection of triamcinolone acetonide may be a good alternative for the treatment of diffuse diabetic macular edema.

Show MeSH
Related in: MedlinePlus